Human interleukin-2

Generic Name: Human interleukin-2

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: -

Unique Ingredient Identifier: FNO32LO217

Background: Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease

Phase 1

Completed

Conditions: Graft Versus Host Disease

Interventions: Drug: Interleukin-2

First Posted Date: 2007-09-14

Last Posted Date: 2020-07-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 29

Registration Number: NCT00529035

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Proleukin and Rapamune in Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: IL-2
Drug: Rapamycin

First Posted Date: 2007-09-06

Last Posted Date: 2017-02-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 9

Registration Number: NCT00525889

Locations: 🇺🇸
Oregon Health Sciences University, Portland, Oregon, United States
🇺🇸
Naomi Berrie Diabetes Center, Columbia University, New York, New York, United States
🇺🇸
Benaroya Research Institute, Seattle, Washington, United States

Biochemotherapy With Temozolomide for Metastatic Melanoma

Phase 2

Terminated

Conditions: Melanoma

Interventions: Drug: Temozolomide
Drug: Velban
Drug: Cisplatin
Drug: Interleukin-2
Drug: Intron-A
Drug: Thalidomide

First Posted Date: 2007-07-23

Last Posted Date: 2020-09-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00505635

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.

Phase 3

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Interferon Alfa-2a
Drug: Interleukin-2

First Posted Date: 2007-07-17

Last Posted Date: 2013-07-10

Lead Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica

Target Recruit Count: 310

Registration Number: NCT00502034

Locations: 🇮🇹
Pavia University Hospital, Pavia, Italy
🇮🇹
Ospedale "Guglielmo da Saliceto", Piacenza, Italy
🇮🇹
Modena University Hospital, Modena, Italy

and more 5 locations

A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma

Phase 2

Terminated

Conditions: Renal Cell Carcinoma

First Posted Date: 2007-06-13

Last Posted Date: 2012-03-08

Lead Sponsor: Endocyte

Target Recruit Count: 12

Registration Number: NCT00485563

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
The Methodist Hospital Research Institute, Houston, Texas, United States

Vaccine Therapy in Treating Patients With Metastatic Cancer

Phase 1

Completed

Conditions: Lung Cancer
Melanoma
Ovarian Sarcoma
Eye Cancer
Adult Soft Tissue Sarcoma
Colorectal Cancer
Breast Cancer
Uterine Sarcoma
Bone Cancer
Colon Cancer

First Posted Date: 2007-03-06

Last Posted Date: 2024-03-04

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020267

Locations: 🇺🇸
Surgery Branch, Bethesda, Maryland, United States

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

Phase 2

Completed

Conditions: Extraocular Extension Melanoma
Recurrent Intraocular Melanoma

First Posted Date: 2007-03-06

Last Posted Date: 2024-03-04

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00020475

Locations: 🇺🇸
Surgery Branch, Bethesda, Maryland, United States

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Recurrent Melanoma
Stage IV Melanoma

First Posted Date: 2007-03-05

Last Posted Date: 2024-03-04

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019448

Locations: 🇺🇸
Surgery Branch, Bethesda, Maryland, United States

Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer

Phase 2

Terminated

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Bevacizumab
Drug: Interleukin-2

First Posted Date: 2007-02-27

Last Posted Date: 2016-03-17

Lead Sponsor: The Methodist Hospital Research Institute

Target Recruit Count: 6

Registration Number: NCT00440973

Locations: 🇺🇸
Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States

Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Phase 1

Completed

Conditions: Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Thymoglobulin
Drug: Busulfan
Drug: Fludarabine
Procedure: Alloreactive NK Infusion
Drug: G-CSF
Drug: Tacrolimus
Drug: Methotrexate
Drug: Interleukin-2

First Posted Date: 2006-11-22

Last Posted Date: 2015-05-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00402558

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy